Companies Dominating the Neuroblastoma Landscape
- Merck & Co., Inc.,
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- United Therapeutics Corporation
- APEIRON Biologics AG
- Sanofi S.A.
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Y- mabs Therapeutics Inc.
- Baxter International Inc.
- Cellectar Biosciences
Browse Key Market Insights with Data Illustration:
In the News
- An acquisition of Acceleron Pharma Inc., by Merck & Co., has been successfully completed. Merck & Co. sought to acquire Acceleron Pharma Inc. in order to expand its portfolio of biopharmaceuticals and build on its current capabilities in the biopharma space. The acquisition will give Merck & Co. access to Acceleron Pharma Inc.'s pipeline of potential new medicines and technologies, as well as provide the ability to better serve patients around the world.
- An agreement has been signed by Pfizer Inc. and Seagen Inc. whereby Pfizer intends to acquire Seagen, a global biotechnology company focused on discovering, developing, and commercializing transformative cancer medicines, with a total enterprise value of USD 43 billion for each Seagen share at USD 229 in cash.
